Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).
about
Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia.Hematopoietic stem cell transplantation for leukemiaAdvances in targeted therapy for chronic myeloid leukemia.Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemiaAdvances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia.Imatinib mesylate in the treatment of hematologic malignancies.Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia.Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients.Current and future management of Ph/BCR-ABL positive ALL.Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment.Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China.Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias.Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
P2860
Q33414592-6998511D-A4E3-45DE-91AB-957943065701Q34034180-2186657D-A25E-40B5-A7D2-F0D2D3014F98Q35160190-9AEB1A92-AEA2-4D82-8B1B-1B4644EFF18CQ35571035-08C1945E-E21C-4780-9203-3CF3A82F314FQ35628978-9EAA21EC-503F-4CA0-8143-18F215C04629Q36600241-49D9E269-1FF8-4F7E-8DE0-52583645533AQ36960525-0E5F139E-A41C-41CB-86D6-C61EDC2CAAF0Q36984852-FF756D33-56B7-45E3-AA1A-1B68959CD781Q37152745-49ECBE5C-434F-4B9E-8E30-7808B69E62AFQ37248354-E16FCD2B-F8A8-4DF5-8A18-5241F5017EFAQ37497977-C0EEFE5D-01C1-4E62-8870-48677E6517E8Q37630453-BE03EEBB-43E5-4AA1-91FB-6C0BDC7E64C8Q38194585-2A623302-2A77-4A3A-8707-D2BB23C37786Q38207017-10AAC080-23A9-4FCF-9F38-08D5B5D514FCQ39503233-9F85D882-B547-4C6E-9F8F-2C681FD5BC06Q41843107-C2FB4726-965E-470E-B7CF-85442925B158Q43168908-2E3E2B01-0AF4-4E6A-AC16-8B7368D67438Q44582795-16B3CF31-31F8-45D2-8B9A-FB70BFAB5FADQ44598654-61C8D400-70B1-4CDF-B6F8-37BC696C36CFQ44931488-FD507AF9-F252-417E-BA48-90CB86F4CF09Q45034611-3C496314-6E9D-4299-88FD-033ADCACE0C9Q46592694-BAFC0A0C-C20A-4562-8CD8-C63A11DF2480Q46846856-3988FC78-F185-4745-A0A1-23D1848F4B44
P2860
Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Therapy with imatinib mesylate ...... mphoblastic leukemia (Ph+ALL).
@en
Therapy with imatinib mesylate
@nl
type
label
Therapy with imatinib mesylate ...... mphoblastic leukemia (Ph+ALL).
@en
Therapy with imatinib mesylate
@nl
prefLabel
Therapy with imatinib mesylate ...... mphoblastic leukemia (Ph+ALL).
@en
Therapy with imatinib mesylate
@nl
P2093
P356
P1433
P1476
Therapy with imatinib mesylate ...... mphoblastic leukemia (Ph+ALL).
@en
P2093
Binckebanck A
Gschaidmeier H
Gökbuget N
Scheuring U
Wassmann B
P2888
P304
P356
10.1038/SJ.LEU.2402770
P577
2002-12-01T00:00:00Z
P5875
P6179
1051275758